The complex is transferred to the nucleus, activating the interferon adjustment factor 1(IRF1), and its transcription activity eventually leads to the anti-tumor effect of the aconic-mediated anti-tumor, and the increased PD-L1 expression (57–60). The gene discussed is IRF1; the disease is neoplasm.